Valued at USD 6.41 billion in 2025, the addiction treatment market is projected to reach USD 6.76 billion in 2026 and USD 10.42 billion by 2034, growing at a CAGR of 5.54% during the forecast period 2026–2034. Growth is anchored in the rising burden of substance use disorder, expanding government support and continued investment in specialized treatment infrastructure, which together shape how care is delivered and how medications reach patients across the global addiction treatment market.

Inpatient and Outpatient Delivery Models

Polaris contrasts two delivery models. Inpatient addiction treatment places patients in a controlled facility with round-the-clock medical supervision and very intense recovery programs; it is more costly and targets severe cases and patients at risk of relapse. Outpatient addiction treatment allows patients to return home after daily sessions, offers flexible, lower-intensity plans at a lower cost and suits mild cases. This split informs capacity planning, staffing and pricing, particularly as demand for detoxification services, rehabilitation and counseling rises together. The six-factor comparison also covers supervision, intensity, cost, targeted patients and recovery environment, giving providers a framework for matching service mix to patient severity.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/global-addiction-treatment-market 

Detoxification Services and Chronic Care Needs

Rising levels of substance use disorder across population groups are increasing the public health burden and driving demand for detoxification services, inpatient rehabilitation and outpatient counseling. This requires substantial investment in specialized therapeutic approaches and is lifting admission rates and length of stay. The chronic, relapsing nature of addiction means patients undergo treatment repeatedly, creating sustained demand, while use of behavioral therapies, pharmacotherapies and long-term recovery support climbs with the patient population.

Hospital Pharmacies Lead Distribution

By distribution channel, the market spans hospital pharmacies, medical stores and others. Hospital pharmacies accounted for the largest revenue share of 45.0% in 2025, owing to the easy availability of medicines at different dose levels and the growing number of hospitals in emerging and underdeveloped regions. Drug awareness campaigns and addiction-free programs run by hospitals also steer individuals toward hospital pharmacies, reinforcing the channel's dominance and making it a priority route to market for manufacturers.

Substance Use Disorder Burden in North America

North America held a 38.0% revenue share in 2025 because the region has among the highest rates of substance use disorder, particularly involving opioids, stimulants and alcohol. SAMHSA data cited by Polaris show 44.6 million individuals aged 12 and above, or 15.3% of the U.S. population, had substance use disorder. Established clinical expertise, specialized facilities, strong reimbursement and public funding, and pharmaceutical and biotech companies leading the commercialization of pharmacotherapies, devices and digital therapeutics all reinforce the region's position. The region's healthcare system also offers the mental health and rehabilitative services that are critical to comprehensive service delivery.

Asia Pacific Growth Momentum

Asia Pacific is expected to register a 6.80% CAGR during 2026–2034. A large younger population in countries such as India is consuming tobacco and alcohol at a rapid pace, while advances in treatment methods and rising government and household healthcare spending allow more individuals to opt for structured programs. High medical tourism and traditional addiction therapy programs in India, China and Japan are also lifting regional revenue. Higher healthcare spending allows individuals to opt for more expensive treatment programs, which helps reduce the incidence of addiction disorder.

Competitive Landscape and Recent Developments

Key players include addiction Treatment Market Indivior plc, Alkermes plc, Hikma Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd., Viatris Inc., Perrigo Company plc, Dr. Reddy's Laboratories Ltd., Cipla Limited, Pfizer Inc. and Haleon plc. Rehabilitation centers, behavioral healthcare organizations and mental healthcare organizations compete by expanding facilities, using telemedicine and investing in digital therapies and remote counseling. In April 2026, DemeRx received FDA acceptance of its IND application for oral noribogaine (DMX-1001) for alcohol use disorder. In March 2026, the National Institute on Drug Abuse published clinical trial results supporting weekly extended-release buprenorphine for opioid use disorder during pregnancy, expected to pave the way for safer alternatives in maternal care.

More Trending Latest Reports By Polaris Market Research:

top-medical-laser-systems-companies-redefining-healthcare-and-aesthetics

top-10-dark-chocolate-manufacturers-in-global-market-2024

saffron-market

cell-culture-matrices-market

uqd-coupling-market

global-age-related-macular-degeneration-amd-market

freeze-drying-equipment-market

ophthalmic-drug-market

non-human-identity-nhi-access-management-market